stockrowScholar Rock Holding Corporation
SRRK Healthcare Biotechnology
Scholar Rock Holding Corporation’s revenue for fiscal 2022 (year ended December 2022) was $33.2 million.
- EPS
- +14.3%
- Free cash flow
- +8.88%
- Total debt
- +294.3%
Quarter to June 2026, against a year earlier
Follow SRRK
Alert me
Scholar Rock Holding Corporation (SRRK) Return on assets
Scholar Rock Holding Corporation's return on assets over the twelve months to 30 June 2026 was −94.6%, down 8.7 percentage points from fiscal 2025 (−86.0%). Over the past ten years it has ranged from −86.0% (fiscal 2025) to −27.0% (fiscal 2019) — the current reading is the lowest in ten years. That is below the Biotechnology industry median of −45.6% and below the Healthcare sector median of −29.3%.
Return on assets, annual
Embed this chart
Annual newest first
| Period | Return on assets | Change (points) |
|---|---|---|
| FY2025 | −86.0% | (23.30) |
| FY2024 | −62.7% | (13.12) |
| FY2023 | −49.6% | (8.95) |
| FY2022 | −40.6% | (2.55) |
| FY2021 | −38.1% | (8.47) |
| FY2020 | −29.6% | (2.58) |
| FY2019 | −27.0% | 13.60 |
| FY2018 | −40.6% | 12.34 |
| FY2017 | −52.9% | (18.61) |
| FY2016 | −34.3% | — |
Against its own ten years
Return on assets against peers
| Company | Return on assets |
|---|---|
| PTCT PTC Therapeutics, Inc. compare | −3.62% |
| MANE Veradermics Incorporated compare | −20.9% |
| BLTE Belite Bio, Inc. Sponsored ADR compare | −21.6% |
| CGON CG Oncology, Inc. compare | −25.1% |
| ERAS Erasca, Inc. compare | −65.3% |
| COGT Cogent Biosciences, Inc. compare | −68.0% |
| IMVT Immunovant, Inc. compare | −71.1% |
| KOD Kodiak Sciences Inc. compare | −94.3% |
| SRRK Scholar Rock Holding Corporation | −94.6% |
| Biotechnology industry median | −45.6% |
| Healthcare sector median | −29.3% |
| Market median | 0.00% |
What Return on assets is
ROA tells an investor how much profit a company earns for shareholders from the assets it uses to run its business.
Annual: Net Income Allotted to Shareholders ÷ Average Assets; TTM: Net Income Allotted to Shareholders ÷ Average Assets (latest quarter)
More on SRRK
- Revenue
- Net income
- EPS (diluted)
- EBITDA
- Free cash flow
- Operating cash flow
- Gross margin
- Operating margin
- Net margin
- Free cash flow margin
- P/E ratio
- P/S ratio
- P/B ratio
- Price to free cash flow
- EV/EBITDA
- EV/Sales
- EV/FCF
- Return on equity
- Return on invested capital
- Debt to equity
- Current ratio
- Total debt
- Shares outstanding
- Book value per share
- Revenue growth
- Altman Z-score
- The full statement